Last checked at 7 Dec 2022 07:00
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or the 'Group')
Product launch in dCELL® division
Launch of VNEW® Fascia Lata allograft used to address stress urinary incontinence
Tissue Regenix (AIM: TRX), the regenerative medical device company, announces the launch of VNEW® Fascia Lata allograft, an additional line extension to the Company's dCELL® division.
The VNEW® Fascia Lata is a soft tissue allograft used to support weakened tissue that can result in stress urinary incontinence ('SUI'), which affects around one-third of adult women at some point in their lives1. The number of women undergoing surgery annually in the US for SUI is around 260,0002.
The VNEW® Fascia Lata allograft is manufactured under an exclusive arrangement for ARMS Medical ('ARMS'), a partner with which Tissue Regenix entered into a multi-year exclusive distribution agreement (the 'Agreement') in 2018. The VNEW® brand is owned by ARMS and consists of uniquely shaped products that address pelvic health needs. The expansion of this Agreement with ARMS adds VNEW® Fascia Lata to the exclusive distribution portfolio of DermaPure® products to hospitals and surgeons throughout the US for use in urology and gynaecology procedures.
Daniel Lee, CEO of Tissue Regenix, commented: "Following the successful launch of VNEW® with ARMS Medical in September 2021, we are very pleased to be continuing our partnership and launching the VNEW® Fascia Lata allograft for surgical procedures to support tissue. The diversification of our product portfolio will contribute to our market penetration, as well as provide a significant improvement to quality of life for those patients that receive these allografts."
Robert Greer, President & Founder of ARMS Medical, stated: "We continue to be passionate about bringing innovative solutions to market for women suffering from pelvic health issues. We are excited about the launch of VNEW® Fascia Lata and credit our strategic partner, Tissue Regenix, and our strong relationships with best-in-class surgeons for making this a reality. Annually, there are over a quarter million women who can benefit and improve their quality of life with ARMS Medical's VNEW® solutions."
1 https://www.urologyhealth.org/urology-a-z/s/stress-urinary-incontinence-(sui)
2 https://www.intechopen.com/chapters/80860
For more information:
Tissue Regenix Group plc | www.tissueregenix.com | |
David Cocke, Chief Financial Officer | Via Walbrook PR | |
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) | Tel: +44(0)20 7710 7600 | |
Ben Maddison / Nick Harland / Kate Hanshaw | ||
Walbrook PR Ltd | Tel: +44(0)20 7933 8780 | |
Alice Woodings / Lianne Applegarth | TissueRegenix@walbrookpr.com | |
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds, which enhance healing opportunities of defects created by trauma and disease. CellRight®'s human osteobiologics may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.